Open Access

LncRNA MEG3 inhibits non‑small cell lung cancer via interaction with DKC1 protein

  • Authors:
    • Zhi Yang
    • Zitong Wang
    • Yong Duan
  • View Affiliations

  • Published online on: June 24, 2020     https://doi.org/10.3892/ol.2020.11770
  • Pages: 2183-2190
  • Copyright: © Yang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Long non‑coding RNA (lncRNA) MEG3 is a key biomarker and therapeutic target in lung cancer; however, its underlying molecular mechanism in lung cancer progression remains unclear. The present study demonstrated a novel regulatory axis in lung cancer, lncRNA MEG3/dyskeratosis congenita 1 (DKC1), and further investigated the effects and molecular mechanism of lncRNA MEG3/DKC1 in lung cancer. RT‑qPCR and western blot analysis were performed to determine gene and protein expression levels. The RNA immunoprecipitation assay was performed to verify binding between lncRNA MEG3 and DKC1. Flow cytometry analysis was performed to assess cell apoptosis, while the Cell Counting Kit‑8 assay was performed to determine cell viability. Transwell and wound healing assays were performed to assess cell invasion and migration, respectively. Telomerase activity was measured using the quantitative TeloTAGGG Telomerase PCR‑ELISA kit. The results demonstrated that lncRNA MEG3 was downregulated, while its binding protein, DKC1, was upregulated in lung cancer cells. Furthermore, lncRNA MEG3 inhibited cell proliferation, migration, invasion and telomerase activity in A549 cells by downregulating DKC1. lncRNA MEG3 inhibited non‑small cell lung cancer progression by inhibiting telomere function, cell proliferation, telomerase activity, cell migration and invasion via regulation of the DKC1 protein expression. LncRNA MEG3/DKC1 was identified as a novel dual‑directional regulatory axis in the present study, acting as a promising target for the treatment of lung cancer.

Related Articles

Journal Cover

September-2020
Volume 20 Issue 3

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Yang Z, Wang Z and Duan Y: LncRNA MEG3 inhibits non‑small cell lung cancer via interaction with DKC1 protein. Oncol Lett 20: 2183-2190, 2020
APA
Yang, Z., Wang, Z., & Duan, Y. (2020). LncRNA MEG3 inhibits non‑small cell lung cancer via interaction with DKC1 protein. Oncology Letters, 20, 2183-2190. https://doi.org/10.3892/ol.2020.11770
MLA
Yang, Z., Wang, Z., Duan, Y."LncRNA MEG3 inhibits non‑small cell lung cancer via interaction with DKC1 protein". Oncology Letters 20.3 (2020): 2183-2190.
Chicago
Yang, Z., Wang, Z., Duan, Y."LncRNA MEG3 inhibits non‑small cell lung cancer via interaction with DKC1 protein". Oncology Letters 20, no. 3 (2020): 2183-2190. https://doi.org/10.3892/ol.2020.11770